Kornimate/medical-research-clean huggingface dataset:
development and feasibility of psycho-educational weight reduction program for young adults

Conditions: Emotional Eating; Obesity

Summary: the main aim of the study was to assess the efficacy of psycho-educational weight reduction program for reducing emotional eating and obesity

all participants who provide written informed consent will go through a screening process to evaluate their eligibility for study entrance after being briefed about the study and any potential risks. individuals who met the eligibility requirements will then be randomly assigned to the control group and the experimental group.

Eligibility criteria:
inclusion criteria: * individuals must be enrolled at a university. * based on world health organizations age range young adults were selected for the current study i-e 19 years to 35 years (who; 2019). exclusion criteria: * the young adults who diagnosed with any chronic health concern, either psychological or physical must not be included in the current study. * the individuals who joined any kind of weight loss program or gym were also not included in the study. * individuals older than 35 were not included in the current study either.

Keywords: psycho-educational weight reduction program
efficacy of nebulized lidocaine, salbutamol, and beclomethasone plus salbutamol in the covid-19 patients with ards on non-invasive ventilation; randomized control trial

Conditions: COVID-19 Acute Respiratory Distress Syndrome

Summary: the covid-19, a pandemic as declare by who1, has a devastating impact on health and economic worldwide2. literature suggests that acute respiratory distress syndrome (ards) develops over 20% of the infected individuals with coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. the current preventative strategies are non-specific10, and current interventions are predominantly supportive1. recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.


Eligibility criteria:
inclusion criteria: * covid-19 positive * moderate to severe ards exclusion criteria: * patients with copd or taking bronchodilators and steroids for chronic respiratory illnesses
chemotherapy related anemia in patients with non-myeloid malignancies

Conditions: Lymphoma; Breast Neoplasms; Lung Neoplasms; Multiple Myeloma; Chronic Lymphocytic Leukemia

Summary: chemotherapy can often cause anemia in patients with cancer. anemia is a low number of red blood cells. the symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath. erythropoietin is a hormone made by the kidneys that signals the bone marrow to produce more red blood cells. recombinant human erythropoietin has been produced in the laboratory and has the same effect as the hormone produced by the body. use of recombinant human erythropoietin allows the body to produce more red blood cells, possibly eliminating or decreasing your symptoms and the need for a red blood cell transfusion. recombinant human erythropoietin is fda approved to treat anemia in cancer patients receiving chemotherapy. this clinical study is investigating the effectiveness of darbepoetin alfa for the treatment of anemia in patients with non-myeloid malignancies who are receiving chemotherapy every three weeks. darbepoetin alfa is a recombinant erythropoietic protein that stimulates the production of red blood cells. this medication has not been approved to treat cancer patients with anemia, however it has been approved by the fda to treat chronic renal failure patients with anemia.


Eligibility criteria:
* patients with non-myeloid malignancies \* patients receiving at least 12 weeks of chemotherapy on a 3-week cycle schedule \* patients with anemia (hgb \>/= 9.0 and \</= 11.0 g/dl)
myelodysplastic syndrome and acute myeloid leukemia related to parp inhibitors (myelorib)

Conditions: Cancer

Summary: although parp inhibitors (parpi) have proved effective in treating many cancers, few patients receiving parpi may experience rare but life-threatening adverse events such as myelodysplastic syndrome (mds) and/or acute myeloid leukaemia (aml). today, data about mds/aml are scarce. the objective was to investigate reports of mds/aml adverse events related to parpi, including olaparib, rucaparib, niraparib, talazoparib and veliparib using the world health organization (who) and the french pharmacovigilance databases.

here, investigators use the world health organization (who) and the french database of individual safety case reports, to identify cases of mds/aml related to parpi.

Eligibility criteria:
inclusion criteria: * case reported in the world health organization (who, also called vigibase) or french database of individual safety case reports at the time of the extraction, * patients treated with at least 1 parpi (with atc classification system): olaparib (atc l01xx46), niraparib (atc l01xx54), rucaparib (atc l01xx55), talazoparib (atc l01xx60), veliparib (none). exclusion criteria: * chronology not compatible between the parpi and adverse event (mds/aml)
activities of daily living in older adults

Conditions: Geriatrics

Summary: in order to maintain independence and prevent disability, it is essential to identify associated factors and reduce functional loss due to concomitant diseases. this study aimed to examine the effects of frailty, balance, and depression on the performance of activities of daily living in older adults. all participants were assessed using the mini mental state test, simple frail scale, geriatric depression scale-short form, and lawton instrumental activities of daily living scale (iadl).

as the global population becomes older, the importance of preserving health, function, and quality of life is being increasingly recognized. in order to maintain independence and prevent disability, it is essential to identify associated factors and reduce functional loss due to concomitant diseases. this study aimed to examine the effects of frailty, balance, and depression on the performance of activities of daily living in older adults. all participants were assessed using the mini mental state test, simple frail scale, geriatric depression scale-short form, and lawton instrumental activities of daily living scale (iadl).

Eligibility criteria:
inclusion criteria: * aged 65 years or older * being able to understand and answer the questionnaires used for data collection * having mental competency as demonstrated by a score higher than 20 on the mini mental state test exclusion criteria: * limited ambulation * psychological problems

Keywords: frailty balance depression activities of daily living
68ga psma pet imaging for the treatment of advanced liver cancer

Conditions: Advanced Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC V8; Stage IV Hepatocellular Carcinoma AJCC V8; Unresectable Hepatocellular Carcinoma

Summary: this phase ii trial tests whether 68-gallium prostate specific membrane antigen (68ga-psma) positron emission tomography (pet) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). psma is a protein that appears in large amounts on the surface of liver cancer cells. the radioactive chemical compound (68ga-psma) has been designed to circulate through the body and attach itself to the psma protein on liver cancer cells. a pet scan is then used to detect the location of the tumor cells. 68ga-psma pet may improve upon the diagnosis and management of liver cancer.

primary objectives: i. to test the performance of novel biomarkers derived from psma pet/computed tomography (ct) to measure response compared to response evaluation criteria in solid tumors (recist) criteria, in advanced hepatocellular carcinoma (hcc) patients treated with immunotherapy. ii. to identify precision imaging biomarkers that can predict response of hcc to novel immunotherapy. outline: patients undergo 68ga psma pet/ct scans at baseline, and after 3, 6, 9, and 12 cycles of standard of care immunotherapy in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed-up every 6 months for 3 years.

Eligibility criteria:
inclusion criteria: * patient with pathologically confirmed hcc not amenable to curative resection, transplantation or ablative therapies * have radiographically measurable disease by recist * eligible for atezolizumab/bevacizumab front line therapy * male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent exclusion criteria: * pregnant and/or breast-feeding patients. a negative pregnancy test within 48 hours of the pet scan * patients with higher than the weight/size limitations of pet/ct scanner
iressa™ (gefitinib) with cisplatin plus radiotherapy for the treatment of previously untreated unresected late stage iii/iv non-metastatic head and neck squamous cell carcinoma

Conditions: Neoplasms, Squamous Cell

Summary: the primary purpose of this study is to assess the effectiveness of zd1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (x-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed stage iii or iva squamous cell carcinoma of the head and neck * no prior surgery or chemotherapy/biological therapy/radiation therapy * measurable disease according to response evaluation criteria in solid tumors (recist) * life expectancy of more than 12 weeks exclusion criteria: * cancers of the nasal space, oral cavity and larynx; or certain lung diseases. * abnormal blood chemistry; uncontrolled respiratory, cardiac, hepatic, or renal disease; or coexisting malignancies.

Keywords: head and neck squamous cell carcinoma head and neck squamous cell cancer squamous cell carcinoma squamous cell cancer
trigger point injection in patients with myofascial pain syndrome

Conditions: Injection Site; Fibromyalgia

Summary: this study aims to compare the effectiveness of blinded versus ultrasound-guided trigger point injections into the trapezius muscle in patients with fms. seventy-five patients with fms will participate in this study. they will be randomly assigned to one of two groups: one group received ultrasound-guided trigger point injections, while the other group received blinded trigger point injections. both groups will follow the same home exercise regimen, which included stretching and posture exercises targeting the trapezius and pectoral muscles. the effectiveness of the treatments was evaluated one month post-treatment. the assessment tools will include the fibromyalgia impact questionnaire (fiq) for function, the visual analog scale (vas) for pain, the beck anxiety inventory (beck-a) for anxiety, and the neck disability questionnaire (ndq) for neck disability.

the primary objectives in treating fibromyalgia syndrome (fms) are to deactivate trigger points, alleviate pain, and remove factors that exacerbate the condition. recently, the use of ultrasound (us) has been advocated to reduce potential complications during trigger point injections and to ensure more effective administration of the treatment.this study aims to compare the effectiveness of blinded versus ultrasound-guided trigger point injections into the trapezius muscle in patients with fms. seventy-five patients with fms will participate in this study. they will be randomly assigned to one of two groups: one group received ultrasound-guided trigger point injections, while the other group received blinded trigger point injections. both groups will follow the same home exercise regimen, which included stretching and posture exercises targeting the trapezius and pectoral muscles. the effectiveness of the treatments was evaluated one month post-treatment. the assessment tools will include the fibromyalgia impact questionnaire (fiq) for function, the visual analog scale (vas) for pain, the beck anxiety inventory (beck-a) for anxiety, and the neck disability questionnaire (ndq) for neck disability.

Eligibility criteria:
inclusion criteria: * patients aged 20-60 years who met the 2013 acr criteria * patients who will be diagnosed with fms and cervical chronic mas according to travel and simons' criteria * patients who had a palpated tense band in the upper trapezius muscle and at least 1 active trigger point exclusion criteria: * patients with a diagnosis of cervical radiculopathy, myelopathy, local or systemic infection, treatment for mas in the last 3 months * patients who have symptom duration less than 3 months * patients with pregnancy status, acute or chronic disease that would cause clinical confusion at the time of the study

Keywords: myofascial pain syndrome injection trigger point
international pachyonychia congenita research registry

Conditions: Pachyonychia Congenita

Summary: international pachyonychia congenita research registry (ipcrr) is a patient registry for those suffering from pachyonychia congenita (pc). pc is an ultra-rare extremely painful skin disorder that causes painful blisters and callus on feet and sometimes hands, thickened nails, cysts and other features. the ipcrr consists of a questionnaire, patient photos, optional physician notes from telephone consultation to validate questionnaire and free genetic testing.

how to participate in ipcrr step one: the ipcrr forms are available online at http://www.pachyonychia.org/patient-registry/. the consent form protects your privacy and the questionnaire gathers important details that distinguish pc from other conditions and helps to identify specific characteristics of each type of pc. you may stop and start as often as needed before completing the forms. if you are not certain about an answer, you may skip that question. step two: take photos as shown in the questionnaire sample photo page. you can upload the images online with the questionnaire. if you prefer, you may email the photos. photos of your pc are very important. note: if you do not have access to a computer and wish to have the ipcrr forms mailed, please contact pc project. step three: when your consent form, questionnaire, and photos are received by pc project, we will have an intake call with you to review your information and to discuss the next steps. step four: if referred for genetic testing, you will then be sent the special saliva test kit (no travel required). usually, only saliva is needed and from only one family member. the sample is collected by spitting into the vial in the kit and then mailing it in the envelope provided. genetic testing is complex and time-consuming - it is not like a sugar test or pregnancy test, and can take many months to be completed, but the testing begins as soon as your sample arrives. when the confirming results are received, a full genetic testing report is provided to you with precise information and suggestions specific to your condition. you may find the report very valuable with physicians or other medical providers as well as for school personnel, employers, disability hearings, or other special needs. all information is held confidentially by pc project and the research is reported anonymously. there is no cost to you for any of these tests or assistance from pc project. you may also request additional consultations as needed.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pachyonychia congenita or similar disorder exclusion criteria: * n/a

Keywords: nail dystrophy plantar keratoderma palmar keratoderma leukokeratosis cysts pain krt17 krt16 krt6a krt6b krt6c
correlation between changes in sex hormone levels and stress urinary incontinence in women

Conditions: Urinary Incontinence,Stress

Summary: the goal of this observational study is to learn about the relationship between stress urinary incontinence and endogenous steroids in women, especially its occurrence and severity with androgens and estrogens. the main questions it aims to answer are: * association between stress urinary incontinence and endogenous steroids in women * risk factors associated with stress urinary incontinence in women participants will be asked to provide basic clinical information as well as results of measurements of serum steroid hormone levels. researchers will compare stress urinary incontinence group and control group to see if the changes of sex hormone levels were statistically significant.

by comparing the differences of six hormones between female patients with stress urinary incontinence (sui) and non-sui patients (patients without pelvic floor muscle dysfunction and lower urinary tract dysfunction) aged ≥20 years, especially the changes of androgen and estrogen levels, the correlation between the changes of hormone levels and stress urinary incontinence was obtained. multivariate logistic regression analysis was used to analyze the relationship between hormones and urinary incontinence, and further correlation analysis was performed for statistically significant hormones. estrogen and androgen were divided into four groups: normal estrogen/normal androgen group, decreased estrogen/normal androgen group, normal estrogen/decreased androgen group, decreased estrogen/decreased androgen group. stratified analysis was performed to analyze whether there was an interaction between the two hormones and exclude confounding effects. finally, the data were further analyzed by sensitivity analysis of baseline characteristics, and the known risk factors were verified in this trial, including age, parity, menopausal status, genetic factors, obesity, and on this basis, the correlation between pelvic surgery history, diabetes, hypertension, smoking and stress urinary incontinence was explored.

Eligibility criteria:
inclusion criteria: - experimental group 1. women aged ≥20 years 2. stress urinary incontinence diagnosed in our hospital; 3. six hormone tests were performed in our hospital; control group (1) women aged ≥20 years; (2) diseases other than stress urinary incontinence diagnosed by our hospital; (2) six hormone tests were performed in our hospital; exclusion criteria: 1. pelvic organ prolapse, overactive bladder, urge urinary incontinence, overflow urinary incontinence, mixed urinary incontinence; 2. patients who received hormone replacement therapy within 6 months; 3. estrogen-dependent diseases, such as endometriosis, uterine leiomyoma, ovarian tumors; 4. the presence of gynecological malignant tumors or other diseases affecting hormone secretion; 5. the presence of nervous system diseases.

Keywords: stress urinary incontinence steroid hormone case-control study
the validity, reliability and interpretability of thai-version of chronic urticaria quality of life questionnaire

Conditions: Chronic Urticaria

Summary: in the majority of patients with the chronic urticaria, the etiology is unclear, leading to difficulties in treatment and high rates of recurrence. according to the international eaaci/ga2len/edf/wao guidelines (the dermatology section of the european academy of allergology and clinical immunology(eaaci), the global allergy and asthma european network (ga2len), the european dermatology forum (edf) and the world allergy organization (wao) in urticaria, using the chronic urticaria quality of life questionnaire in a routine management is the key for a better treatment outcome. to translate this questionnaire into thai is essential in our subject of interest in order to effectively apply it to local patients. the thai-version questionnaire will encourage enhanced as well as impactful therapeutic options for thai chronic urticaria patients.

1. adaption of the cu-q2ol questionnaire into thai version by using forward-backward translation that is independently performed by two bilingual translators. the original italian version is translated into thai by two thai native speakers, then the study team reviews the thai-version cu-q2ol questionnaire for items comprehensibility and integrates the first consensus version which re-translated into italian by an italian native speaker afterwards. the comparison between the backward italian version cu-q2ol questionnaire and the original cu-q2ol is carried out to find out whether there are any misconception and mistranslation in the intermediary forward version of questionnaire. after that, the second consensus version will be tested on 15 chronic urticaria patients to detect any misunderstanding points based on patients' comments. finally, this thai-version of cu-q2ol questionnaire will be used to investigate the validity, reliability, interpretability and minimal clinical important difference. 2. to investigate the validity, reliability and interpretability of thai-version of chronic urticaria quality of life questionaire (cu-q2ol), the severity of chronic urticaria symptoms will be assessed by investigators and patients using the urticaria activity score (uas7), the dlqi and cu-q2ol questionnaire.

Eligibility criteria:
inclusion criteria: * age 18 years old or above * diagnosed as chronic urticaria based on "the eaaci/ga(2)len/edf/wao guideline * literate in thai language and can complete the questionnaire by themselves exclusion criteria: * have other active skin diseases * have a psychiatric problem * cannot understand the questionnaire by themselves.

Keywords: chronic urticaria cu-q2ol